Backed by a former J&J CEO, the startup plans to advance its drug candidates into late-stage trials.
AI Biotech Enveda Doubles in Value to $2 Billion
Source: WSJ Technology
The Edge of the Cyber World See the latest
Backed by a former J&J CEO, the startup plans to advance its drug candidates into late-stage trials.
Source: WSJ Technology